Refactor Capital
Actively deployingBurlingame · Seed
Investment thesis
Refactor's investment thesis centers on backing founders who are refactoring the real world through hard tech innovation at the seed stage. The portfolio spans transformative sectors including biotech, medtech, robotics, energy, and climate solutions. The firm prioritizes early-stage investments in ventures addressing fundamental challenges in healthcare, sustainability, and emerging technologies, seeking to be a founder's first institutional call and providing hands-on support throughout the journey.
Source: firm website, verified Jul 20, 2026.
What they invest in
from 6 of 6 portfolio companiesHealthtech ×5AI & Machine Learning ×3Biotech ×2Advanced Manufacturing ×1Cleantech ×1Climate Tech ×1Consumer ×1Deep Tech ×1
HQs:United States×6
Investments · 6 tracked
founders shown can be your intro pathSolugen develops a biomanufacturing platform using fermentation and bioprocessing technology to produce specialty chemicals at scale. The company serves customers in energy, chemicals, and related industries with cost-effective alternatives to traditional petrochemical-based manufacturing.
Advanced ManufacturingBiotechCleantechClimate TechHealthtechHouston, US
Sean Hunt(Co-founder)inGaurab Chakrabarti(Co-founder & CEO)in
Ophelia provides medication-assisted treatment for opioid addiction through a telemedicine platform, allowing patients to receive care without attending residential rehab. The service is designed for individuals struggling with opioid addiction who prefer privacy-respecting, home-based treatment options.
Digital HealthHealthtechWellness & FitnessNew York City, US
Mattan Griffel(Founder)inZack Gray(Founder)inDr. Arthur Robin Williams(Codesigner)Dr. Adam Bisaga(Codesigner)
Orchid provides an electronic health record system with AI capabilities for solo and small-group mental health practices, handling administrative tasks and clinical documentation to reduce manual work.
AI & Machine LearningHealthtechSaaSSan Francisco, US
Joseph Pomianowski(Founder)in
Orchid is a personal assistant that operates via text messaging to help users with organization, information retrieval, and task completion. It integrates with users' existing tools and apps to automate habits, manage administrative tasks, and track personal details.
AI & Machine LearningConsumerEnterprise SoftwareFuture of WorkSan Francisco, US
Parallel Bio develops human immune organoids and computational tools to predict drug efficacy across diverse patient populations, replacing animal testing in drug discovery. The company aims to accelerate pharmaceutical development and reduce clinical trial failure rates through human-first biological prediction models.
AI & Machine LearningBiotechDeep TechHealthtechSan Francisco, US
Robert DiFazio(Founder)inJuliana Hilliard(Founder)inRobertJuliana
Shield Bio develops nanopore sequencing technology for clinical use, designed to run rapid genetic tests in healthcare settings. The company initially targets infectious disease diagnosis and sepsis detection to reduce treatment delays.
HealthtechMedical DevicesSan Francisco, US
Fred Turner(Founder/CEO)in
Frequently asked questions
- What stage does Refactor Capital invest at?
- Refactor Capital invests at the Seed stage.
- What is Refactor Capital's typical check size?
- Refactor Capital typically writes checks of $1M – $2M.
- What sectors does Refactor Capital focus on?
- Refactor Capital focuses on AgTech, AI & Machine Learning, Biotech, Climate Tech, Deep Tech, Defense Tech, Energy, FemTech, Healthtech, Medical Devices, Mental Health, Robotics.
- Where is Refactor Capital located?
- Refactor Capital is headquartered in Burlingame, US.
Similar investors
Everywhere Ventures is an early-stage venture capital firm backing founders across diverse sectors and geographies. The firm provides pre-seed and seed capital, actively supports portfolio companies through its founder community, and has demonstrated success in introducing investments to subsequent funding rounds.
Data Collective identifies and supports ambitious company founders developing technology-driven solutions. The firm focuses on companies using innovation to restore predictability in an unstable world, with demonstrated expertise across clean energy, gene therapy, sustainable agriculture, and machine learning applications in healthcare.
Innovestor is a Nordic investment group active across early-stage platforms including Angel CoFund, Life Science Fund, and Growth Fund III. The firm completed 74 investments in 2025 (23 initial and 51 follow-on rounds) and achieved a €24 million real estate exit. Innovestor also operates Energy Storage and Corporate Venturing investment platforms.
Khosla Ventures is a venture capital firm investing across consumer and retail, enterprise, fintech, frontier technologies, sustainability, digital health, medtech and diagnostics, and therapeutics sectors.
ICI Fund is a US-based venture capital firm that invests in Israeli founders developing deep technology and enterprise software solutions powered by artificial intelligence. The firm focuses on B2B pre-seed and seed stage companies, leads rounds, and actively supports portfolio company growth in the US market through its network of business executives.